ODM-216 Enters Clinic With No Disclosed Targets: Strategic Signal, Not Evidence Event

Orion Pharma Doses First Patient in Phase 1/2 BICIDES Trial for ODM-216

Orion Pharma has announced the dosing of the first patient in its Phase 1/2 BICIDES study, evaluating ODM-216, an experimental bispecific antibody. This marks a significant milestone as ODM-216 is the company's first biologic and immuno-oncology cancer drug candidate to advance into clinical development. The trial aims to assess the safety, pharmacokinetics, and preliminary efficacy of ODM-216 in patients with various advanced solid tumors. This move strengthens Orion's immuno-oncology pipeline and signifies an expansion of its research and development capabilities into large molecule biologics, aligning with its long-term global R&D strategy.

• The initiation of the BICIDES study with ODM-216 represents a pivotal achievement for Orion Pharma, marking its first biologic and immuno-oncology drug candidate to enter clinical development. This advancement underscores Orion's commitment to expanding its expertise beyond small chemical molecules into large molecule biologics, reinforcing its long-term global R&D strategy.
• The Phase 1/2 BICIDES study is designed to evaluate the safety, pharmacokinetics, and preliminary efficacy of ODM-216. The trial targets patients suffering from various advanced solid tumors, aiming to assess how the experimental bispecific antibody, which simultaneously targets PVRIG and PD-L1, performs in a clinical setting.
• ODM-216 is an experimental bispecific antibody developed by Orion Pharma to activate the body's immune responses against tumors. By simultaneously targeting the PVRIG and PD-L1 pathways, it represents an innovative approach within immuno-oncology, forming a key part of Orion's growing portfolio in this critical therapeutic area.

Unpacking the BICIDES Phase 1/2 Trial Design

Several recent phase 1/2 trials have evaluated novel agents across a range of advanced solid tumor indications, spanning targeted therapies, antibody-drug conjugates, and combination immunotherapy regimens. The studies vary in design — from accelerated titration dose-escalation to multicohort open-label frameworks — and employ endpoints including ORR, PFS, OS, DLT, and MTD. The table below summarizes key design parameters and endpoints across these trials.

Addressing Unmet Needs in Advanced Solid Tumors

Clinical research in advanced solid tumors has increasingly focused on populations with limited therapeutic options — including patients who have progressed on prior immunotherapy, those harboring specific oncogenic mutations, and tumor types with historically poor response to standard regimens. Across multiple disease settings, investigators are targeting molecularly defined subgroups and refractory populations to address gaps left by existing standard-of-care therapies.

• Immunotherapy-refractory and immunotherapy-naive NPC patients: In advanced nasopharyngeal carcinoma, a clear efficacy differential exists between immunotherapy-naive patients (ORR 33.3%, median PFS 10.8 months with LBL-007 plus toripalimab) and IO-treated patients (ORR 11.8%, median PFS 2.7 months), underscoring the unmet need in the post-immunotherapy relapsed setting and the opportunity to optimize first-line combination strategies.

• KRAS G12C-mutant solid tumors: Adagrasib in KRAS G12C-mutant populations demonstrated a median OS of 14.74 months and median PFS of 6.80 months across 400 patients, with a DCR of 83%, yet frequent adverse events and dose modifications highlight ongoing tolerability challenges. Additionally, the high prevalence of brain metastases in KRAS G12C-positive non-small cell lung cancer has driven development of brain-penetrant KRAS G12C inhibitors, representing a distinct and underserved subpopulation.

• Heavily pretreated colorectal and head and neck cancers: Patients with metastatic colorectal cancer who have received ≥2 prior lines of systemic therapy remain a high-priority unmet need; famitinib plus camrelizumab yielded an ORR of 13.6% and median OS of 10.9 months in this setting. Similarly, in relapsed/refractory advanced HNSCC following platinum-based chemotherapy and anti-PD-(L)1 therapy, sacituzumab govitecan achieved an ORR of 16% and median OS of 9.0 months, reflecting the limited options available after standard second-line treatment.

• HLA-G-expressing and biomarker-selected tumor populations: JNJ-78306358, targeting HLA-G-expressing tumors (colorectal, ovarian, and renal cell carcinoma), represents an effort to exploit a tumor-selective antigen in heavily pretreated patients, though CRS-related toxicities limited dose escalation to potentially efficacious levels, with no objective responses observed and only 2 patients achieving stable disease >40 weeks.

• Tissue-agnostic and molecularly defined populations: The expansion of pan-cancer biomarker-driven therapy — encompassing NTRK, BRAF V600E, RET, HER2-positive, MSI-high, and TMB-high — alongside emerging candidates such as FGFR, ALK, MET, ROS1, NRG1, PIK3CA, AKT, KRAS G12C, HER2 mutations, HER2-low/ultralow, B7-H3, and tumor-infiltrating lymphocytes (TILs), reflects a paradigm shift toward histology-agnostic targeting, with tumor heterogeneity and lineage-specific molecular dependencies remaining key challenges to broader clinical integration.

• Patients with low or negative PD-L1 expression in refractory solid tumors: Cadonilimab, a bispecific antibody targeting PD-1 and CTLA-4 simultaneously, has demonstrated antitumor activity in advanced cervical cancer, hepatocellular carcinoma, non-small cell lung cancer, and gastric cancer, with notable efficacy even in patients with low or negative PD-L1 expression — addressing a population historically underserved by PD-1 monotherapy.

Orion Pharma's Strategic Leap into Immuno-Oncology Biologics

Orion Pharma's announcement of dosing the first patient in its Phase 1/2 BICIDES study for ODM-216 marks a pivotal moment, signaling a bold strategic pivot for a company with a notable history in drug development. Historically recognized for its success in small molecule therapies, such as the 'first-in-class' catechol O-methyltransferase (COMT) inhibitor entacapone for Parkinson's disease, Orion Pharma is now venturing into the complex and rapidly evolving landscape of biologics and immuno-oncology. This move represents not just an expansion of its pipeline but a fundamental shift in its research and development focus.

The decision to advance a bispecific antibody for advanced solid tumors underscores a commitment to diversifying its therapeutic portfolio. While the company has a proven track record of bringing novel therapies to market, as evidenced by entacapone's impact on Parkinson's treatment, the transition to large molecule biologics and immuno-oncology presents distinct challenges. Developing biologics requires specialized expertise in discovery, manufacturing, and clinical development, areas that differ significantly from small molecule programs. This implies a potential lack of established internal expertise and infrastructure specific to large molecules, which could lead to unforeseen development hurdles. Furthermore, the efficacy of their first immuno-oncology biologic in advanced solid tumors is entirely unproven, representing a significant clinical risk given the novelty of the approach for the company. This strategic shift also carries the risk of straining Orion Pharma's R&D resources, potentially diverting focus or capital from established programs.

This strategic evolution, however, also presents substantial opportunities. By leveraging its foundational R&D capabilities and scientific acumen, Orion Pharma aims to establish a new foothold in cancer treatment. The success of this early-phase trial will be critical in validating its expanded capabilities and determining the future trajectory of its immuno-oncology ambitions. The market will be watching closely to see if Orion Pharma can replicate its past success in a new, highly complex arena.